{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T13:20:27Z","timestamp":1783171227446,"version":"3.54.6"},"reference-count":14,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["XHYY202301"],"award-info":[{"award-number":["XHYY202301"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["23DZ2291800"],"award-info":[{"award-number":["23DZ2291800"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008839","name":"Shanghai Xuhui District Central Hospital","doi-asserted-by":"publisher","award":["2023007"],"award-info":[{"award-number":["2023007"]}],"id":[{"id":"10.13039\/501100008839","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.clinthera.2026.04.010","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T11:20:42Z","timestamp":1778844042000},"page":"615-622","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Assessing the Potential Clinical Drug-Drug Interactions Between D-1553 (Garsorasib) and CYP450 Enzymes\/Transporters via a Cocktail Approach"],"prefix":"10.1016","volume":"48","author":[{"given":"Qian","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qichen","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijian","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjie","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2492-3219","authenticated-orcid":false,"given":"Jingying","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.clinthera.2026.04.010_bib0001","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1111\/cas.15829","article-title":"D-1553: a novel KRASG12C inhibitor with potent and selective cellular and in vivo antitumor activity","volume":"114","author":"Shi","year":"2023","journal-title":"Cancer Sci"},{"issue":"7","key":"10.1016\/j.clinthera.2026.04.010_bib0002","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jtho.2023.03.015","article-title":"D-1553 (Garsorasib), a potent and selective inhibitor of KRASG12C in patients with NSCLC: phase 1 study results","volume":"18","author":"Li","year":"2023","journal-title":"J Thorac Oncol"},{"issue":"8","key":"10.1016\/j.clinthera.2026.04.010_bib0003","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S2213-2600(24)00110-3","article-title":"Garsorasib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial","volume":"12","author":"Li","year":"2024","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.clinthera.2026.04.010_bib0004","article-title":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use","year":"2024","journal-title":"ICH harmonised guideline drug interaction studies M12"},{"key":"10.1016\/j.clinthera.2026.04.010_bib0005","unstructured":"FDA, Clinical drug interaction studies\u2014cytochrome P450 enzyme- and transporter-mediated drug interactions guidance for industry. 2020. Accessed May 15, 2024"},{"issue":"9","key":"10.1016\/j.clinthera.2026.04.010_bib0006","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1002\/jps.24489","article-title":"The use of transporter probe drug cocktails for the assessment of transporter-based drug-drug interactions in a clinical setting-proposal of a four component transporter cocktail","volume":"104","author":"Ebner","year":"2015","journal-title":"J Pharm Sci"},{"issue":"9","key":"10.1016\/j.clinthera.2026.04.010_bib0007","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70028","article-title":"Drug-drug interactions of icenticaftor (QBW251) with a 5-probe cytochrome P450 cocktail and oral contraceptives","volume":"17","author":"Huth","year":"2024","journal-title":"Clin Transl Sci"},{"issue":"10","key":"10.1016\/j.clinthera.2026.04.010_bib0008","doi-asserted-by":"crossref","first-page":"938","DOI":"10.3390\/pharmaceutics12100938","article-title":"The development and validation of a novel ``dual cocktail'' probe for cytochrome P450s and transporter functions to evaluate pharmacokinetic drug-drug and herb-drug interactions","volume":"12","author":"Kwon","year":"2020","journal-title":"Pharmaceutics"},{"issue":"9","key":"10.1016\/j.clinthera.2026.04.010_bib0009","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1002\/jcph.2447","article-title":"Value of assessing 1-hydroxymidazolam in drug-drug interaction studies with midazolam as a substrate of cytochrome P450 3A","volume":"64","author":"Magliocca","year":"2024","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.clinthera.2026.04.010_bib0010","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1053\/j.gastro.2006.02.034","article-title":"Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics","volume":"130","author":"Ho","year":"2006","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.clinthera.2026.04.010_bib0011","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1124\/dmd.116.072397","article-title":"Inhibition of intestinal OATP2B1 by the calcium receptor antagonist ronacaleret results in a significant drug-drug interaction by causing a 2-fold decrease in exposure of rosuvastatin","volume":"45","author":"Johnson","year":"2017","journal-title":"Drug Metab Dispos"},{"issue":"51","key":"10.1016\/j.clinthera.2026.04.010_bib0012","doi-asserted-by":"crossref","first-page":"32939","DOI":"10.1021\/acsomega.0c03930","article-title":"Contribution of Uptake and Efflux Transporters to Oral Pharmacokinetics of Furosemide","volume":"5","author":"Chapa","year":"2020","journal-title":"ACS Omega"},{"issue":"9","key":"10.1016\/j.clinthera.2026.04.010_bib0013","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/s00228-012-1258-x","article-title":"Itraconazole and domperidone: a placebo-controlled drug interaction study","volume":"68","author":"Yoshizato","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.clinthera.2026.04.010_bib0014","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/jcph.562","article-title":"Best practices for the use of itraconazole as a replacement for ketoconazole in drug-drug interaction studies","volume":"56","author":"Liu","year":"2016","journal-title":"J Clin Pharmacol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929182600113X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929182600113X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T12:52:16Z","timestamp":1783169536000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014929182600113X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":14,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S014929182600113X"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2026.04.010","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessing the Potential Clinical Drug-Drug Interactions Between D-1553 (Garsorasib) and CYP450 Enzymes\/Transporters via a Cocktail Approach","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2026.04.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}